Alzamend Neuro (ALZN) Short Interest Ratio & Short Volume $2.20 -0.05 (-2.22%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.19 -0.01 (-0.45%) As of 08/1/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Alzamend Neuro Short Interest DataAlzamend Neuro (ALZN) has a short interest of 89,000 shares, representing 3.16% of the float (the number of shares available for trading by the public). This marks a 2.30% increase in short interest from the previous month. The short interest ratio (days to cover) is 0.1, indicating that it would take 0.1 days of the average trading volume of 234,197 shares to cover all short positions.Current Short Interest89,000 sharesPrevious Short Interest87,000 sharesChange Vs. Previous Month+2.30%Dollar Volume Sold Short$282.13 thousandShort Interest Ratio0.1 Days to CoverLast Record DateJuly 15, 2025Outstanding Shares2,900,000 sharesFloat Size2,820,000 sharesShort Percent of Float3.16%Today's Trading Volume101,989 sharesAverage Trading Volume234,197 sharesToday's Volume Vs. Average44% Short Selling Alzamend Neuro? Sign up to receive the latest short interest report for Alzamend Neuro and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartALZN Short Interest Over TimeALZN Days to Cover Over TimeALZN Percentage of Float Shorted Over Time Alzamend Neuro Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 7/15/202589,000 shares $282.13 thousand +2.3%3.2%0.1 $3.17 6/30/202587,000 shares $253.17 thousand -36.1%11.2%0.1 $2.91 6/15/2025136,100 shares $440.96 thousand -80.7%17.5%0.1 $3.24 5/31/2025705,700 shares $2.84 million +386.0%92.0%0.5 $4.03 5/15/2025145,200 shares $477.71 thousand -18.6%18.9%1.2 $3.29 4/30/2025178,300 shares $1.06 million -20.3%2.8%0.4 $5.94 4/15/2025223,800 shares $170.09 thousand -37.6%3.5%0.6 $0.76 3/31/2025358,600 shares $340.06 thousand +196.6%5.7%1 $0.95 3/15/2025120,900 shares $81.87 thousand -47.0%1.9%0.3 $0.68 2/28/2025228,200 shares $187.12 thousand +332.2%4.4%0.6 $0.82 Get the Latest News and Ratings for ALZN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Alzamend Neuro and its competitors with MarketBeat's FREE daily newsletter. 2/15/202552,800 shares $57.55 thousand -33.0%1.0%0.1 $1.09 1/31/202578,800 shares $89.44 thousand +6.1%1.5%0.6 $1.14 1/15/202574,300 shares $86.93 thousand +130.8%1.4%0.5 $1.17 12/31/202432,200 shares $37.35 thousand -48.8%0.6%0.2 $1.16 12/15/202462,900 shares $74.85 thousand -52.7%1.2%0.3 $1.19 11/30/2024132,900 shares $172.77 thousand -7.9%3.1%0.6 $1.30 11/15/2024144,300 shares $196.25 thousand -35.2%3.4%0.5 $1.36 10/31/2024222,500 shares $349.33 thousand -2.6%5.3%0.1 $1.57 10/15/2024228,400 shares $381.43 thousand +121.3%5.4%0.1 $1.67 9/30/2024103,200 shares $174.41 thousand +47.9%3.0%0.1 $1.69 9/15/202469,800 shares $134.71 thousand +2.8%2.4%0 $1.93 8/31/202467,900 shares $159.57 thousand +162.2%10.7%0 $2.35 8/15/202425,900 shares $50.76 thousand +50.6%4.1%0 $1.96 7/31/202417,200 shares $61.40 thousand +126.3%2.1%1 $3.57 7/15/20247,600 shares $28.35 thousand +153.3%1.3%0.7 $3.73 6/30/202429,900 shares $11.79 thousand -68.6%0.5%0.4 $0.39 6/15/202495,100 shares $43.22 thousand +65.7%1.8%1.2 $0.45 5/31/202457,400 shares $33.87 thousand -30.1%1.1%0.9 $0.59 5/15/202482,100 shares $50.90 thousand +264.9%1.7%1 $0.62 4/30/202422,500 shares $16.00 thousand +55.2%0.5%0.3 $0.71 4/15/202414,500 shares $10.75 thousand -68.0%0.3%0.3 $0.74 3/31/202445,300 shares $45.30 thousand -11.5%0.9%0.8 $1.00 3/15/202451,200 shares $47.62 thousand +13.0%1.0%0.9 $0.93 2/29/202445,300 shares $40.77 thousand +2.5%0.9%0.7 $0.90 2/15/202444,200 shares $39.02 thousand +4.5%0.9%0.8 $0.88 1/31/202442,300 shares $36.38 thousand -41.5%0.9%0.3 $0.86 1/15/202472,300 shares $70.45 thousand -2.8%1.9%0.5 $0.97 12/31/202374,400 shares $66.22 thousand -43.5%2.1%0.6 $0.89 12/15/2023131,700 shares $131.70 thousand -29.5%3.7%1 $1.00 11/30/2023186,900 shares $226.15 thousand +379.2%5.7%1.6 $1.21Buffett to put 90% of his money in this one stock? (Ad)CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accounting firms like Deloitte and KPMG, Joel Litman (who’s also a member of the Global CFA Institute) figured out a unique, less-risky way to grow rich in the stock market. Litman says you don’t need dozens of investments, overpriced advisers, or hedge funds. You just need these 3 stocks, which have helped Litman’s own mom earn 3,400%.Click here to view… 11/15/202339,000 shares $58.50 thousand -18.2%1.2%0.4 $1.50 10/31/202347,700 shares $1.25 million -92.1%1.5%2.3 $26.26 10/15/2023602,000 shares $124.01 thousand +30.0%1.2%2.8 $0.21 9/30/2023463,200 shares $109.78 thousand +82.8%1.0%2.2 $0.24 9/15/2023253,400 shares $60.82 thousand +17.3%0.5%1.3 $0.24 8/31/2023216,000 shares $56.64 thousand -60.7%0.4%1.2 $0.26 8/15/2023549,900 shares $169.92 thousand +8.9%1.2%2.8 $0.31 7/31/2023505,200 shares $228.86 thousand +2.6%1.1%3 $0.45 7/15/2023492,500 shares $247.24 thousand +4.0%1.1%3.1 $0.50 6/30/2023473,700 shares $241.59 thousand +13.0%1.1%2.9 $0.51 6/15/2023419,400 shares $285.19 thousand -44.9%0.9%2.5 $0.68 5/31/2023761,400 shares $552.93 thousand +44.0%1.7%4.2 $0.73 5/15/2023528,600 shares $274.71 thousand -11.1%1.2%3.2 $0.52 4/30/2023594,400 shares $325.32 thousand -8.6%1.3%3.5 $0.55 4/15/2023650,500 shares $382.04 thousand +10.9%1.4%3.4 $0.59 3/31/2023586,500 shares $249.26 thousand -18.2%1.3%2.9 $0.43 3/15/2023717,000 shares $343.73 thousand -0.4%1.6%2.4 $0.48 2/28/2023719,600 shares $386.35 thousand +5.1%1.6%2.4 $0.54 2/15/2023685,000 shares $401.48 thousand -31.1%1.5%2.2 $0.59 1/31/2023994,100 shares $659.78 thousand +11.2%2.2%2.8 $0.66 1/15/2023893,700 shares $529.96 thousand -44.8%2.0%2.5 $0.59 12/30/20221,620,000 shares $915.14 thousand +3.2%4.5%4.4 $0.56 12/15/20221,570,000 shares $1.40 million -7.7%4.4%3.6 $0.89 11/30/20221,700,000 shares $1.96 million -20.6%5.8%3.3 $1.15 11/15/20222,140,000 shares $2.40 million +27.4%7.3%4 $1.12 10/31/20221,680,000 shares $1.97 million -11.1%5.4%2.9 $1.17 10/15/20221,890,000 shares $1.98 million -34.2%5.5%3.1 $1.05 9/30/20222,870,000 shares $3.42 million +221.9%8.4%4.8 $1.19 9/15/2022891,700 shares $1.11 million -33.0%2.6%1.9 $1.24 8/31/20221,330,000 shares $1.20 million +112.9%3.9%3.7 $0.91 8/15/2022624,800 shares $649.79 thousand -40.5%1.8%1.6 $1.04 7/31/20221,050,000 shares $933.56 thousand -10.3%3.4%2.9 $0.89 7/15/20221,170,000 shares $1.09 million +17.2%4.0%2.3 $0.93 6/30/2022998,700 shares $863.28 thousand -4.9%3.5%1.4 $0.86 6/15/20221,050,000 shares $888.30 thousand -37.9%3.6%1.2 $0.85 5/31/20221,690,000 shares $1.59 million +79.0%5.8%1.4 $0.94 5/15/2022943,900 shares $884.81 thousand -41.0%2.4%0.7 $0.94 4/30/20221,600,000 shares $1.63 million +28.0%4.0%1.3 $1.02 4/15/20221,250,000 shares $1.30 million +51.0%3.2%1 $1.04 3/31/2022827,900 shares $1.02 million +83.2%2.1%0.6 $1.23 3/15/2022452,000 shares $411.32 thousand -11.1%1.2%0.3 $0.91 2/28/2022508,400 shares $594.83 thousand +2.1%1.3%0.2 $1.17 2/15/2022497,900 shares $687.10 thousand -22.1%1.3%0.1 $1.38 1/31/2022638,900 shares $977.52 thousand -73.0%1.7%0.2 $1.53 1/15/20222,370,000 shares $4.24 million +13.4%5.8%0.4 $1.79 12/31/20212,090,000 shares $3.97 million -10.3%5.2%0.3 $1.90 12/15/20212,330,000 shares $6.03 million +37.9%5.8%0.3 $2.59 11/30/20211,690,000 shares $3.62 million -39.4%4.3%0.3 $2.14 11/15/20212,790,000 shares $6.39 million +335.1%7.1%0.5 $2.29 10/29/2021641,200 shares $1.37 million +1.6%1.6%0.1 $2.14Buffett to put 90% of his money in this one stock? (Ad)CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accounting firms like Deloitte and KPMG, Joel Litman (who’s also a member of the Global CFA Institute) figured out a unique, less-risky way to grow rich in the stock market. Litman says you don’t need dozens of investments, overpriced advisers, or hedge funds. You just need these 3 stocks, which have helped Litman’s own mom earn 3,400%.Click here to view… 10/15/2021631,400 shares $1.51 million +126.2%1.6%0.3 $2.39 9/30/2021279,100 shares $859.63 thousand -50.5%0.7%0.1 $3.08 9/15/2021563,700 shares $1.48 million +8.3%1.5%0.3 $2.63 8/31/2021520,700 shares $1.59 million +281.2%1.4%0.2 $3.06 8/13/2021136,600 shares $475.37 thousand No Change0.4%0.1 $3.48 ALZN Short Interest - Frequently Asked Questions What is Alzamend Neuro's current short interest? Short interest is the volume of Alzamend Neuro shares that have been sold short but have not yet been closed out or covered. As of July 15th, traders have sold 89,000 shares of ALZN short. 3.16% of Alzamend Neuro's shares are currently sold short. Learn More on Alzamend Neuro's current short interest. What is a good short interest percentage for Alzamend Neuro? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 3.16% of Alzamend Neuro's floating shares are currently sold short. Is Alzamend Neuro's short interest increasing or decreasing? Alzamend Neuro saw a increase in short interest during the month of July. As of July 15th, there was short interest totaling 89,000 shares, an increase of 2.3% from the previous total of 87,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Alzamend Neuro's float size? Alzamend Neuro currently has issued a total of 2,900,000 shares. Some of Alzamend Neuro's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Alzamend Neuro currently has a public float of 2,820,000 shares. How does Alzamend Neuro's short interest compare to its competitors? 3.16% of Alzamend Neuro's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Alzamend Neuro: Lixte Biotechnology Holdings, Inc. (5.43%), Imunon, Inc. (0.07%), Aprea Therapeutics, Inc. (1.31%), LakeShore Biopharma Co., Ltd. (2.56%), Novogen Limited (4.48%), Cellectar Biosciences, Inc. (2.58%), Sensei Biotherapeutics, Inc. (0.87%), Kiora Pharmaceuticals, Inc. (1.84%), Biomerica, Inc. (2.95%), Traws Pharma, Inc. (3.30%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Coinbase Global, Inc. ($5.11 billion), Charter Communications, Inc. ($4.76 billion), Reddit Inc. ($2.84 billion), SoFi Technologies, Inc. ($2.79 billion), Seagate Technology Holdings PLC ($2.79 billion), Live Nation Entertainment, Inc. ($2.67 billion), Rocket Lab Corporation ($2.49 billion), AST SpaceMobile, Inc. ($2.12 billion), Moderna, Inc. ($2.09 billion), and Omnicom Group Inc. ($2.04 billion). View all of the most shorted stocks. What does it mean to sell short Alzamend Neuro stock? Short selling ALZN is an investing strategy that aims to generate trading profit from Alzamend Neuro as its price is falling. ALZN shares are trading down $0.05 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Alzamend Neuro? A short squeeze for Alzamend Neuro occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ALZN, which in turn drives the price of the stock up even further. How often is Alzamend Neuro's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ALZN, twice per month. The most recent reporting period available is July, 15 2025. More Short Interest Resources from MarketBeat Related Companies Lixte Biotechnology Short Interest Data Imunon Short Interest Data Aprea Therapeutics Short Interest Data LakeShore Biopharma Short Interest Data Novogen Short Interest Data Cellectar Biosciences Short Interest Data Sensei Biotherapeutics Short Interest Data Kiora Pharmaceuticals Short Interest Data Biomerica Short Interest Data Traws Pharma Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ALZN) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alzamend Neuro, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alzamend Neuro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALZN Stock Alerts